UGCG

UGCG is the rate-limiting glucosylceramide synthase that glycosylates ceramide to produce glucosylceramide de novo, the precursor for all glycosphingolipids, and through this single biochemical step it governs membrane lipid composition, organelle homeostasis, and a broad range of survival and signaling outputs (PMID:29409484, PMID:36504340). Its in vitro activity has been directly demonstrated using deuterated ceramide as acceptor substrate with LC-MS/MS detection of glucosylceramide product, enabling kinetic and inhibitor characterization (PMID:36504340). By converting pro-apoptotic ceramide into glycosphingolipids, UGCG promotes cell survival: in AML cells UGCG inhibition causes ceramide accumulation that triggers the GRP78/PERK/CHOP ER-stress axis and activates RAB32-driven, DRP1-dependent mitochondrial fission via ER-mitochondria communication (PMID:41734065), and its glycosphingolipid products build GM1+ membrane microdomains in plasma membranes and lysosomes that confer resistance to lysosomal autophagy inhibition (PMID:36331284). UGCG-derived glycosphingolipids also remodel membrane lipid rafts and organellar lipid pools, supporting CD8+ T cell raft integrity and effector function [PMID:bio_10.1101_2024.10.10.617261], altering ER/mitochondrial sphingolipid composition and metabolic flux in breast cancer (PMID:31666638, PMID:32424263), and the UGCG product GM3 suppresses insulin receptor-β in liver sinusoidal endothelial cells to shape hepatic insulin sensitivity (PMID:40906894). Downstream of this lipid output, UGCG potentiates ERK, NF-κB, Wnt/β-catenin, STAT3, Akt, and GSK3β signaling in cancer and cardiac contexts, in part through a synergistic interaction with the lactosylceramide synthase B4GalT5 (PMID:37658291, PMID:39674092, PMID:39934657). UGCG is further required for lysosomal homeostasis and autophagic flux, controlling antiviral STING signaling (PMID:39631580), and for glycosphingolipid-dependent endocytic recycling of the Notch ligand Delta that regulates intestinal secretory-cell fate [PMID:bio_10.1101_2025.02.04.636335].

1. 2018 Medium

   Established UGCG as the de novo glucosylceramide synthase whose overexpression tracks with multidrug resistance, framing it as a survival-associated lipid enzyme rather than a passive metabolic step.

   Evidence Review synthesizing prior biochemical and cell biology data on GlcCer synthase activity and MDR1 correlation

   PMID:29409484

   Open questions at the time

   • No single new experiment; enzymatic mechanism summarized not directly tested here
   • Causal link between UGCG and MDR1 not dissected
2. 2019 Medium

   Showed that beyond lipid synthesis, UGCG reprograms nutrient metabolism, linking the enzyme to glutamine uptake and oxidative stress handling that sustain proliferation.

   Evidence UGCG overexpression in MCF-7 cells with metabolite measurements and metabolic assays

   PMID:31666638

   Open questions at the time

   • Single cell line and lab
   • Mechanism connecting glycosphingolipid output to glutamine metabolism not resolved
   • No loss-of-function confirmation
3. 2020 Medium

   Extended the metabolic role by showing UGCG shifts cells to an energetic phenotype and alters ER/mitochondrial sphingolipid composition, linking the enzyme to organelle lipid remodeling.

   Evidence UGCG overexpression in MCF-7 with Seahorse flux assays and lipidomics of subcellular fractions

   PMID:32424263

   Open questions at the time

   • Single lab overexpression model
   • Causal lipid species driving metabolic shift not identified
   • No in vivo validation
4. 2023 High

   Provided a direct in vitro enzymatic assay establishing UGCG kinetics and inhibitor pharmacology, anchoring downstream phenotypes to measurable catalytic activity.

   Evidence In vitro assay with deuterated ceramide substrate and LC-MS/MS product quantitation in cell homogenates and human fibroblasts

   PMID:36504340

   Open questions at the time

   • No structural model of substrate engagement
   • Acceptor/donor specificity beyond ceramide not mapped
5. 2023 High

   Connected UGCG glycosphingolipid output to specific membrane microdomain formation, explaining how the enzyme confers resistance to lysosomal autophagy inhibition.

   Evidence Proteomics, lipidomics, gain/loss-of-function with eliglustat in cancer cells plus syngeneic and PDX models

   PMID:36331284

   Open questions at the time

   • Molecular composition and assembly of GM1+ microdomains not fully defined
   • How microdomains mechanistically block cell death incompletely resolved
6. 2023 Medium

   Identified a direct physical partner, B4GalT5, showing UGCG acts synergistically with downstream lactosylceramide synthesis to drive cardiomyocyte hypertrophy via ERK and mitochondrial oxidative stress.

   Evidence Co-IP, UGCG knockdown/overexpression and B4GalT5 knockdown epistasis in cardiomyocytes, in vivo pressure overload model

   PMID:37658291

   Open questions at the time

   • Co-IP without reciprocal/structural validation of the interaction interface
   • Whether B4GalT5 partnership operates outside cardiac context unknown
7. 2024 Medium

   Demonstrated that UGCG maintains lysosomal homeostasis and autophagic flux to restrain STING signaling, revealing a role in antiviral defense.

   Evidence shRNA knockdown and pharmacological inhibition with autophagy flux assays, lysosomal pH, LC3-STING Co-IP, and in vivo PRV models

   PMID:39631580

   Open questions at the time

   • Direct lipid mediator linking UGCG to lysosomal pH not identified
   • Single lab
8. 2024 Medium

   Linked UGCG to NF-κB and Wnt/β-catenin pathway activation underlying chemoresistance and malignant progression in TNBC.

   Evidence Gain/loss-of-function in TNBC lines with pathway inhibitor rescue

   PMID:39674092

   Open questions at the time

   • How glycosphingolipid output activates these pathways mechanistically unclear
   • No in vivo confirmation of pathway dependency
9. 2024 Low

   Suggested UGCG remodels endosomal membranes affecting cargo trafficking, by showing overexpression relieves endosomal polyplex sequestration.

   Evidence UGCG overexpression in HEK293 with transfection efficiency and endosomal imaging readouts

   PMID:38327808

   Open questions at the time

   • Single functional readout with mechanistic link inferred not demonstrated
   • No loss-of-function or lipid-level confirmation
10. 2025 Medium

    Showed UGCG supports β-adrenergic-driven cardiac fibrosis through ERK, STAT3, Akt and GSK3β signaling, identifying it as a druggable node with miglustat.

    Evidence siRNA knockdown in primary cardiac fibroblasts plus in vivo isoproterenol model with miglustat

    PMID:39934657

    Open questions at the time

    • Direct lipid species coupling UGCG to these kinases not defined
    • Single lab
11. 2025 High

    Established that the specific UGCG product GM3 suppresses insulin receptor-β in liver endothelial cells, mechanistically connecting glycosphingolipid synthesis to systemic insulin sensitivity.

    Evidence LSEC-specific conditional Ugcg knockout mice, LC-MS ganglioside quantitation, EM of fenestration, cocultures and inhibitor treatment

    PMID:40906894

    Open questions at the time

    • Molecular basis of GM3-IRβ interaction not structurally defined
    • Generality across endothelial beds untested
12. 2026 High

    Defined the survival mechanism most directly: UGCG glycosylates ceramide to blunt apoptosis, and its inhibition triggers an ER-stress and RAB32/DRP1 mitochondrial-fission axis that synergizes with venetoclax in AML.

    Evidence Genetic and eliglustat inhibition with venetoclax, ER-stress and RAB32 activation assays, mitochondrial fission analysis in primary AML cells and xenografts

    PMID:41734065

    Open questions at the time

    • Spatial details of ceramide-driven ER-mitochondria contact remodeling incomplete
    • Whether axis generalizes beyond AML untested
13. 2025 Medium

    Connected UGCG to RNA m6A regulation, showing its inhibition downregulates METTL3 to destabilize mutant p53 mRNA and reduce cancer stem cells, re-sensitizing resistant colon cancer.

    Evidence CRISPR knockout and Genz-161 inhibition with lipidomics, m6A and METTL3 analysis, xenografts (preprint)

    PMID:bio_10.1101_2025.11.02.686136

    Open questions at the time

    • Preprint not peer-reviewed
    • Mechanistic link from glycosphingolipids to METTL3 expression unresolved
14. 2025 Medium

    Revealed a developmental role: UGCG/GlcT glycosphingolipid output drives Notch-ligand Delta endocytic recycling, controlling secretory-cell fate in mammalian intestine and Drosophila.

    Evidence Conditional intestinal UGCG knockout in mice and Drosophila genetic epistasis with metabolite rescue (preprint)

    PMID:bio_10.1101_2025.02.04.636335

    Open questions at the time

    • Preprint not peer-reviewed
    • Direct demonstration of which GSL species mediates Delta recycling in mammals incomplete
15. 2024 Medium

    Showed UGCG-dependent glycosphingolipid synthesis is required for CD8+ T cell lipid raft integrity and effector function, linking the enzyme to anti-tumor immunity.

    Evidence 13C UDP-glucose tracing and genetic inhibition in CD8+ T cells with raft, granzyme and in vivo tumor readouts (preprint)

    PMID:bio_10.1101_2024.10.10.617261

    Open questions at the time

    • Preprint not peer-reviewed
    • Which raft glycosphingolipids sustain TCR signaling not pinpointed

• How a single glucosylceramide synthase coordinates such divergent outputs—ER-stress survival, membrane microdomains, ganglioside-receptor regulation, Notch recycling, and immune raft signaling—through distinct downstream glycosphingolipid species remains unresolved.
• No structural model of UGCG catalysis or substrate selectivity
• Specific glycosphingolipid species mediating each phenotype not individually mapped
• Mechanism coupling lipid product to NF-κB/Wnt/STAT3 signaling not established